Iqvia Holdings Inc.




Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-02-21 pm EST 5-day change 1st Jan Change
237.3 USD +1.07% Intraday chart for Iqvia Holdings Inc. -2.54% +2.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Deutsche Bank Raises IQVIA Holdings Price Target to $280 From $245, Maintains Buy Rating MT
North American Morning Briefing : S&P 500 Seen -2- DJ
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
UBS Adjusts IQVIA Holdings Price Target to $300 From $240, Maintains Buy Rating MT
Barclays Adjusts Price Target on IQVIA to $265 From $260, Maintains Overweight Rating MT
Baird Adjusts Price Target on IQVIA Holdings to $251 From $226, Maintains Neutral Rating MT
Guggenheim Downgrades IQVIA Holdings to Neutral From Buy MT
Tranche Update on IQVIA Holdings Inc.'s Equity Buyback Plan announced on October 31, 2013. CI
Equity Markets Bounce Back Following Tuesday's Selloff MT
Equity Markets Rebound Following Tuesday's Selloff MT
Equities Rebound Intraday Following Tuesday's Selloff MT
IQVIA Soars on Upbeat 2024 Guidance Following Quarterly, Annual Beats MT
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday MT
Transcript : IQVIA Holdings Inc., Q4 2023 Earnings Call, Feb 14, 2024
IQVIA quarterly results beat estimates on strong demand for research services RE
IQVIA Holdings' Q4 Adjusted Earnings, Revenue Up; 2024 Outlook Issued, Pre-Bell Share Prices Rise MT
Earnings Flash (IQV) IQVIA HOLDINGS Posts Q4 Revenue $3.87B, vs. Street Est of $3.80B MT
Earnings Flash (IQV) IQVIA HOLDINGS Posts Q4 EPS $2.84, vs. Street Est of $2.82 MT
IQVIA Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IQVIA Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
IQVIA Holdings Inc. Provides Earnings Guidance for the Full Year of 2024 CI
North American Morning Briefing :Stock Futures -2- DJ
'No Landing' scenarios swirl as markets recoil RE
BTIG Initiates IQVIA Holdings With Buy Rating, $285 Price Target MT
Bausch + Lomb Q4 Likely to See Moderating Forex Headwinds, Focus on 2024 Guidance, RBC Says MT
Chart Iqvia Holdings Inc.
More charts
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
234.8 USD
Average target price
270.7 USD
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Iqvia Holdings Inc. - Nyse
  4. News Iqvia Holdings Inc.
  5. Earnings Flash (IQV) IQVIA Reports Q3 Revenue $3.74B, vs. Street Est of $3.777B
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance